VivoSeq
Oncology

Acute Myeloid Leukaemia (AML)

0

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Acute Myeloid Leukaemia (AML) is an early-stage landscape with 0 programs across 5 companies. The most active players are AstraZeneca, Hikma Pharmaceuticals LLC, Jiangsu Hansoh Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalH

Hikma Pharmaceuticals LLC

0 programs

PreclinicalJiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalC

Clavis Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed9 · 75%
Terminated1 · 8%
Unknown status1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
Active, not recruiting·HHikma Pharmaceuticals LLC·N/A·NCT06572982·20 enrolled
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
Completed·AstraZeneca logoAstraZeneca·Phase 2/3·NCT00952588·74 enrolled
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
Completed·TTC Biopharm·Phase 1·NCT03790072·10 enrolled
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
Completed·HHikma Pharmaceuticals LLC·Phase 1·NCT06326697·32 enrolled
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT01019161·5 enrolled
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
Completed·Mmedac GmbH·Phase 2·NCT01063660·75 enrolled
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Completed·Amgen logoAmgen·Phase 2·NCT00114764·84 enrolled
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00530699·30 enrolled
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Completed·CClavis Pharma·Phase 3·NCT01147939·381 enrolled
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
Completed·UUniversity Hospital Southampton NHS Foundation Trust·Phase 1/2·NCT01422603·9 enrolled
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Terminated·TTC Biopharm·Phase 2·NCT05358808·16 enrolled
Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
Unknown status·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT02140606

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)